吉妥珠单抗奥唑米星在复发难治性急性髓系白血病中的应用：来自土耳其的多中心真实世界数据。
Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey.
作者信息
Küçükdiler Ayşe Hilal Eroğlu, Yavaşoğlu İrfan, Selim Cem, Mutlu Cansu Atmaca, Karakuş Abdullah, Koyuncu Mahmut Bakır, Bilgir Oktay, Ayyıldız Orhan, Tiftik Eyüp Naci, Bolaman Ali Zahit
机构信息
Aydin Adnan Menderes University Faculty of Medicine, Department of Hematology, Turkey.
Izmir Bozyaka Training and Research Hospital, Department of Adult Hematology, Turkey.
出版信息
Leuk Res Rep. 2021 Nov 17;16:100280. doi: 10.1016/j.lrr.2021.100280. eCollection 2021.
We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with intermediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.
我们回顾性评估了吉妥珠单抗奥唑米星（GO）在复发难治性（R/R）急性髓系白血病（AML）患者中的应用。本研究纳入了在4个血液学中心接受GO单药治疗的21例CD33阳性R/R AML患者。中位年龄为59岁，中位东部肿瘤协作组（ECOG）体能状态评分为2分。根据细胞遗传学分析，1例患者为低危，12例为中危，8例为高危。总缓解率为52.3%。8例高危患者中有3例获得部分缓解。33.3%的患者出现3级贫血。80%的患者出现4级中性粒细胞减少和血小板减少。1例患者因GO的副作用导致窦性阻塞综合征/静脉闭塞性疾病（SOS/VOD）死亡。GO可被视为R/R AML患者挽救治疗的一个良好选择。
Zotero 插件